ArticleTrials2025
Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares (HBOT-UC): study protocol for a multi-center, randomized, double-blind, sham-controlled trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05987852 (Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial
Who cites it
1 citing paper in PubMed.
- Perioperative hyperbaric oxygen therapy: mechanisms, evidence, and clinical application.Medical gas research · 2027Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis. Hyperbaric oxygen therapy involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. It reduces systemic and local inflammation and up-regulates hypoxia response pathways, making it an attractive therapeutic option. In this trial we aim to confirm the treatment benefits of hyperbaric oxygen therapy for hospitalized ulcerative colitis patients and assess the long-term durability of treatment effect.
methodsThis prospective, double-masked, multicenter, 1:1 randomized, sham-controlled trial will enroll 126 participants with known or newly diagnosed ulcerative colitis hospitalized for an acute moderate to severe flare. Participants will be randomized to either hyperbaric oxygen therapy with steroids or sham air with steroids. The trial will involve a 5-day intervention period followed by a 12-month observational period with a 90-day standard of care visit and 12-month telephone visit. The primary outcome measure is clinical response defined as complete resolution of rectal bleeding and improvement in stool frequency, without need for in-hospital biologics, small molecules, or colectomy by study day 5. Secondary endpoints include additional key patient-reported outcomes and histo-endoscopic measures of disease activity. DISCUSSION: Novel and effective treatments are needed for this population to optimize disease outcomes while minimizing treatment-related risks. Demonstrating the ability of hyperbaric oxygen therapy to improve clinical response to steroids and avoid in-hospital rescue therapy has the potential to change the management of hospitalized ulcerative colitis flares.
trial registrationClinicalTrials.gov NCT05987852. Registered on August 14, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.